2011
DOI: 10.1002/jso.22028
|View full text |Cite
|
Sign up to set email alerts
|

Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion

Abstract: In-transit melanoma metastases are often confined to a limb. In this circumstance, treatment by isolated limb perfusion or isolated limb infusion can be a remarkably effective regional treatment option.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
24
0
1

Year Published

2013
2013
2017
2017

Publication Types

Select...
5
1
1

Relationship

2
5

Authors

Journals

citations
Cited by 37 publications
(25 citation statements)
references
References 65 publications
(70 reference statements)
0
24
0
1
Order By: Relevance
“…Melphalan remains the principal agent used in isolated limb perfusion for the treatment of in-transit metastases from melanoma [90]. The first to investigate the pharmacokinetics of intraperitoneally delivered melphalan were Alberts et al, [91].…”
Section: Melphalanmentioning
confidence: 99%
“…Melphalan remains the principal agent used in isolated limb perfusion for the treatment of in-transit metastases from melanoma [90]. The first to investigate the pharmacokinetics of intraperitoneally delivered melphalan were Alberts et al, [91].…”
Section: Melphalanmentioning
confidence: 99%
“…When compared with ILP, ILI is technically simpler, has a significantly shorter treatment duration, may be considered in a broader group of patients (medically compromised, frail and elderly patients), and is possible with regional anesthesia. 32 Melphalan, a nitrogen mustard alkylating agent, is the chemotherapeutic agent most commonly used with ILP/ILI. Modification of melphalan-based regimens with addition of tumor necrosis factor alpha (TNF) has been well described with somewhat conflicting outcomes.…”
Section: Primary Limb Perfusion/infusionmentioning
confidence: 99%
“…In general, metaanalysis reveals higher complete response rates for patients treated with melphalan-based limb perfusion with the addition of TNF. 32 Current evidence indicates a role for ILP in the management of unresectable locoregional in-transit disease, but no role as a routine prophylactic adjuvant measure after standard surgery for patients with highrisk melanoma on a limb. 32-34 A recent metaanalysis of 22 studies involving ILP for unresectable locally advanced melanoma of the limb yielded a median complete response rate of 58% and a median overall response rate of 90%, with higher response rates for melphalan with TNF compared to melphalan alone.…”
Section: Primary Limb Perfusion/infusionmentioning
confidence: 99%
See 2 more Smart Citations